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Abstract
Following the submission of application EFSA-GMO-RX-013 under Regulation (EC) No 1829/2003 from
Syngenta Crop Protection NV/SA, the EFSA Panel on Genetically Modiﬁed Organisms (GMO) was asked
to deliver a scientiﬁc risk assessment on the data submitted in the context of the renewal of
authorisation application for the insect-resistant genetically modiﬁed maize MIR604, for food and feed
uses, excluding cultivation within the EU. The data received in the context of this renewal application
contained post-market environmental monitoring reports, a systematic search and evaluation of
literature, updated bioinformatic analyses, and additional documents or studies performed by or on
behalf of the applicant. The GMO Panel assessed these data for possible new hazards, modiﬁed
exposure or new scientiﬁc uncertainties identiﬁed during the authorisation period and not previously
assessed in the context of the original application. Under the assumption that the DNA sequence of
the event in maize MIR604 considered for renewal is identical to the corrected sequence of the
originally assessed event, the GMO Panel concludes that there is no evidence in renewal application
EFSA-GMO-RX-013 for new hazards, modiﬁed exposure or scientiﬁc uncertainties that would change
the conclusions of the original risk assessment on maize MIR604.
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Summary
Following the submission of application EFSA-GMO-RX-013 under Regulation (EC) No 1829/20031
from Syngenta Crop Protection NV/SA, the EFSA Panel on Genetically Modiﬁed Organisms (GMO) was
asked to deliver a scientiﬁc risk assessment on the data submitted in the context of the renewal of
authorisation application for the insect-resistant genetically modiﬁed (GM) maize MIR604. The scope of
the application EFSA-GMO-RX-013 is for the renewal of the placing on the market of products
containing, consisting of, or produced from maize MIR604, excluding cultivation within the European
Union (EU).
In delivering its scientiﬁc opinion, the GMO Panel took into account application EFSA-GMO-RX-013,
additional information provided by the applicant, scientiﬁc comments submitted by the EU Member
States and relevant scientiﬁc publications. The data received in the context of the renewal application
EFSA-GMO-RX-013 contained: post-market environmental monitoring reports, an evaluation of the
literature retrieved by a systematic search, updated bioinformatics analyses, and additional studies
performed by or on behalf of the applicant. The GMO Panel assessed these data for possible new
hazards, modiﬁed exposure or new scientiﬁc uncertainties identiﬁed during the authorisation period
and not previously assessed in the context of the original application.
Under the assumption that the DNA sequence of the event in maize MIR604 considered for renewal
is identical to the corrected sequence of the originally assessed event, the GMO Panel concludes that
there is no evidence in the renewal application EFSA-GMO-RX-013 for new hazards, modiﬁed exposure
or scientiﬁc uncertainties that would change the conclusions of the original risk assessment on maize
MIR604 (EFSA, 2009).
1 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. OJ L 268, 18.10.2003, p. 1–23.
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1. Introduction
1.1. Background
On 23 August 2018, the European Food Safety Authority (EFSA) received from the European
Commission application EFSA-GMO-RX-013 for the renewal of the authorisation of maize MIR604
(Unique Identiﬁer SYN-IR6Ø4-5), submitted by Syngenta Crop Protection NV/SA (hereafter referred to
as ‘the applicant’) according to Regulation (EC) No 1829/2003.2
Following receipt of application EFSA-GMO-RX-013, EFSA informed the Member States (MS) and
made the summary of the application available to the public on the EFSA website.3
EFSA checked the application for compliance with the relevant requirements of Regulation (EC)
No 1829/2003 and Regulation (EU) No 503/20134 and, when needed, asked the applicant to
supplement the initial application. On 5 November 2018, EFSA declared the application valid and made
the application available to the MS and the European Commission.
Following the submission of application EFSA-GMO-UK-2005-11 and the publication of the
EFSA scientiﬁc opinion (EFSA, 2009), the placing on the market of maize MIR604 for products
containing, consisting of, or produced from this GM maize, excluding cultivation in the EU, was
authorised by Commission Decision 2009/866/EC.5 A copy of this authorisation was provided by the
applicant.6
From the validity date, EFSA and its scientiﬁc Panel on Genetically Modiﬁed Organisms (hereafter
referred to as ‘the GMO Panel’) endeavoured to respect a time limit of 6 months to issue a scientiﬁc
opinion on application EFSA-GMO-RX-013. Such time limit was extended whenever EFSA and/or its
GMO Panel requested supplementary information to the applicant. According to Regulation (EC)
No 1829/2003, any supplementary information provided by the applicant during the risk assessment
was made available to the EU Member States and European Commission (for further details, see the
section ‘Documentation’, below). In accordance with Regulation (EC) No 1829/2003, EFSA consulted
the nominated risk assessment bodies of the MS, including national Competent Authorities within the
meaning of Directive 2001/18/EC.7 The MS had three months to make their opinion known on
application EFSA-GMO-RX-013 as of date of validity.
1.2. Terms of Reference as provided by the requestor
According to Articles 6 and 18 of Regulation (EC) No 1829/2003, EFSA and its GMO Panel were
requested to carry out a scientiﬁc risk assessment of maize MIR604 for the renewal of the
authorisation for placing on the market of products containing, consisting of, or produced from GM
maize MIR604 in the context of its scope as deﬁned in application EFSA-GMO-RX-013.
According to Regulation (EC) No 1829/2003, this scientiﬁc opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation including the opinions of the nominated risk
assessment bodies of the MS.8
In addition to the present scientiﬁc opinion on maize MIR604, EFSA and its GMO Panel were also
asked to report on the particulars listed under Articles 6(5) and 18(5) of Regulation (EC) No 1829/2003.
The relevant information is made available in the EFSA Register of Questions,9 including the information
required under Annex II to the Cartagena Protocol, a labelling proposal, a post-market environmental
monitoring (PMEM) plan as provided by the applicant; the method(s), validated by the Community
2 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. OJ L 268, 18.10.2003, p. 1–23.
3 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionDocumentsLoader?question=EFSA-Q-2018-00644
4 Commission Implementing Regulation (EU) No 503/2013 of 3 April 2013 on applications for authorisation of genetically
modiﬁed food and feed in accordance with Regulation (EC) No 1829/2003 of the European Parliament and of the Council and
amending Commission Regulations (EC) No 641/2004 and (EC) No 1981/2006. OJ L 157, 8.6.2013, p. 1–48.
5 Commission Decision of 30 November 2009 authorising the placing on the market of products containing, consisting of, or
produced from genetically modiﬁed maize MIR604 (SYN-IR6Ø4-5) pursuant to Regulation (EC) No 1829/2003 of the European
Parliament and of the Council. Ofﬁcial Journal of the European Union L 314/102, 30.11.2009.
6 Dossier: Maize MIR604 – Section 2.1
7 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modiﬁed organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.
8 Opinions of the nominated risk assessment bodies of EU Member States can be found at the EFSA Register of Questions,
http://registerofquestions.efsa.europa.eu/roqFrontend/login, querying the assigned Question Number.
9 http://registerofquestions.efsa.europa.eu/roqFrontend/questionDocumentsLoader?question=EFSA-Q-2018-00644
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reference laboratory, for detection, including sampling, identiﬁcation of the transformation event in the
food-feed and/or foods-feeds produced from it and the appropriate reference materials.
2. Data and methodologies
2.1. Data
The data for application EFSA-GMO-RX-013 provided by the applicant at the time of submission, or
in reply to requests for additional information, are speciﬁed below.
In the context of this renewal application, no new sequencing study was submitted among the
additional documents or studies performed by or on behalf of the applicant. In accordance with the
GMO Panel guidelines for renewal of applications of GM food and feed authorised under Regulation
(EC) No 1829/2003 (EFSA GMO Panel, 2015a), the GMO Panel evaluated the data provided in the
context of this maize MIR604 renewal application under the assumption that the MIR604 event
sequence is identical to the corrected sequence of the originally assessed event (EFSA GMO Panel,
2015b).
2.1.1. Post-market monitoring reports10
Based on the outcome of the initial food and feed risk assessment, a post-market monitoring plan
for monitoring of GM food and feed was not required by the authorisation decision. The
implementation of a PMEM plan, consisting of a general surveillance plan to check for any adverse
effects on the environment arising from maize MIR604, was a condition for the authorisation. As no
potential adverse environmental effects were identiﬁed in the environmental risk assessment of maize
MIR604 (EFSA, 2009), case-speciﬁc monitoring was not considered necessary by the GMO Panel.
The applicant provided nine annual PMEM reports covering a reporting period from July 2009 till
June 2018. The annual PMEM plans submitted by the applicant included (1) commodity crop (GM and
non-GM) imports into the EU by country of origin and destination; (2) the description of a centralised
system established by EuropaBio for the collection of information recorded by various operators
(federations involved in maize grains import and processing) on any observed adverse effect(s) on
human health and the environment arising from handling of maize possibly containing maize MIR604;
(3) the reports of the surveillance activities conducted by such operators; and (4) the review of
relevant scientiﬁc peer-reviewed studies retrieved from literature searches.
2.1.2. Systematic search and evaluation of literature11
In addition to the nine separate searches provided as part of the annual PMEM reports, the
applicant performed a systematic literature search covering the period from January 2007 till March
2019, in accordance with the recommendations on literature search outlined in EFSA (2010, 2017a).
Searches in electronic bibliographic databases and in websites of relevant organisations were
performed to identify relevant publications. Altogether, 2968 publications were retrieved (after removal
of duplicates). After applying the eligibility/inclusion criteria deﬁned a priori by the applicant, 16
publications were identiﬁed as relevant for food and feed safety assessment, molecular
characterisation and environmental safety assessment. The list of relevant publications is provided in
Appendix A.
2.1.3. Updated bioinformatic data12
At the time of submission of the renewal dossier, the applicant provided a complete bioinformatic
dataset for maize MIR604 event including an analysis of the insert and ﬂanking sequences, an analysis
of the potential similarity to allergens and toxins of the newly expressed proteins and of all possible
open reading frames (ORFs) within the insert and spanning the junction sites, and an analysis of
possible horizontal gene transfer (HGT) (EFSA, 2017b). Additionally, upon EFSA request during the risk
assessment, the applicant provided bioinformatic analysis using up-to-date databases to identify
possible gene interruption, to asses potential for horizontal gene transfer, and to assess the capacity of
10 Dossier: Maize MIR604 – Section 2.2; additional information: 15/5/2019.
11 Dossier: Maize MIR604 – Section 2.3.1; additional information: 2/5/2019.
12 Dossier: Maize MIR604 – Section 2.3.2; additional information: 15/5/2019.
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the newly expressed proteins mCry3A and PMI to trigger celiac disease (EFSA GMO Panel, 2017). The
outcome of the updated bioinformatic analyses is presented in Section 3.3.
2.1.4. Additional documents or studies provided by the applicant13
In line with the renewal guidance requirements (EFSA GMO Panel, 2015a), the applicant provided
an overview on the worldwide approvals of maize MIR604 and the full reports of all studies performed
by or on behalf of the applicant over the course of the authorisation period and not previously
submitted to the EU (Appendix B).
The relevance of the listed studies for molecular characterisation, human and animal safety and the
environment was assessed by the applicant.
2.1.5. Overall assessment as provided by the applicant14
The applicant provided an overall assessment concluding that information provided in the
application for renewal of authorisation of maize MIR604 for food and feed uses in the EU does not
change the outcome of the original risk assessment (EFSA, 2009).
2.1.6. Monitoring plan and proposal for improving the conditions of the original
authorisation15
The applicant indicated in the dossier that the PMEM plan is appropriate and does not need any
changes.
2.2. Methodologies
The GMO Panel assessed the application for renewal of the authorisation of maize MIR604 for food
and feed uses in accordance with Articles 11 and 23 of Regulation (EC) No 1829/2003. The GMO
Panel took into account the requirements described in its guideline for the risk assessment of renewal
applications of GM food and feed authorised under Regulation (EC) No 1829/2003 (EFSA GMO Panel,
2015a). The comments raised by the nominated risk assessment bodies of the EU Member States were
taken into consideration during the scientiﬁc risk assessment.9
3. Assessment
3.1. Evaluation of the post-market monitoring reports
During the general surveillance activities covering the authorisation period of maize MIR604, no
adverse effects were reported by the applicant.
3.2. Evaluation of the systematic search and evaluation of literature
The GMO Panel assessed the applicant’s literature search on maize MIR604 and the newly
expressed proteins mCry3A and PMI. The overall quality of the performed literature search is
acceptable; however, the GMO Panel considers that future searches could be ﬁne-tuned. The GMO
Panel recommends the applicant for future searches to:
 deﬁne more clearly the eligibility/inclusion criteria for assessing the relevance of publications; ensure that enough search term variation is used (covering possible synonyms, related terms,
acronyms, spelling variants, old and new terminology, brand and generic names, lay and
scientiﬁc terminology, common typos, translation issues);
 ensure that enough truncation is used and used consistently; include controlled vocabulary (subject indexing) in the searches when available (in addition to
text words);
 adapt the search to the size of the retrieved publications (and thus not combine search sets
when one of the search sets already yields only a small number of publications).
13 Dossier: Maize MIR604 – Section 2.3.3; additional information: 15/5/2019.
14 Dossier: Maize MIR604 – Section 3.
15 Dossier: Maize MIR604 – Section 4.
Assessment of genetically modiﬁed maize MIR604 for renewal authorisation
www.efsa.europa.eu/efsajournal 7 EFSA Journal 2019;17(11):5846
The GMO Panel acknowledges that no publications raising a safety concern for human and animal
health and the environment which would change the original risk assessment conclusions on maize
MIR604 (EFSA, 2009) have been identiﬁed by the applicant.
3.3. Evaluation of the updated bioinformatic data
The results of the updated bioinformatic analyses of maize MIR604 conﬁrm that no known
endogenous genes were disrupted by the insert. Analyses of the amino acid sequence of the newly
expressed mCry3A and PMI proteins show no relevant similarities to toxins, allergens or immunogenic
gluten-related epitopes. In addition, bioinformatic analyses of the newly created ORFs within the insert
or spanning the junctions with genomic DNA conﬁrm previous conclusions indicating that the
expression of ORFs showing similarities to toxins or allergens for the event MIR604 is highly unlikely
(EFSA, 2009; EFSA GMO Panel, 2019).
The updated bioinformatic analysis for maize event MIR604 does not reveal any DNA sequence that
could provide sufﬁcient length and identity which could facilitate double homologous recombination
(HR), conﬁrming the previous conclusions (EFSA GMO Panel, 2019). Given the results of this analysis
and that the recombinant DNA in maize MIR604 does not confer selective advantages or increased
ﬁtness to microorganisms, the GMO Panel identiﬁed no safety concern linked to an unlikely but
theoretically possible HGT.
3.4. Evaluation of the additional documents or studies provided by the
applicant
The GMO Panel evaluated the full study reports of the additional studies provided (Appendix B).
This new information does not raise any concern for human and animal health and the environment,
which would change the original risk assessment conclusions on maize MIR604.
3.5. Evaluation of the overall assessment as provided by the applicant
The GMO Panel evaluated the overall assessment provided by the applicant and conﬁrms that there
is no evidence in renewal application EFSA-GMO-RX-013 indicating new hazards, relevant changes in
exposure or scientiﬁc uncertainties that would change previous conclusions on maize MIR604.
3.6. Evaluation of the monitoring plan and proposal for improving the
conditions of the original authorisation
The PMEM plan covers general surveillance of imported GM plant material, including maize MIR604.
This general surveillance is coordinated by EuropaBio and implemented by selected operators
(federations involved in maize grains import and processing). In addition, the applicant reviews
relevant scientiﬁc publications retrieved from literature searches on an annual basis. The GMO Panel is
of the opinion that the scope of the plan provided by the applicant is consistent with the scope of
application EFSA-GMO-RX-013, but reminds that monitoring is related to risk management, and thus
the ﬁnal adoption and implementation of the PMEM plan falls outside the mandate of EFSA.
4. Conclusions
Under the assumption that the DNA sequence of the event in maize MIR604 considered for renewal
is identical to the corrected sequence of the originally assessed event (EFSA GMO Panel, 2015b), the
GMO Panel concludes that there is no evidence in renewal application EFSA-GMO-RX-013 for new
hazards, modiﬁed exposure or scientiﬁc uncertainties that would change the conclusions of the original
risk assessment on maize MIR604 (EFSA, 2009).
Documentation as provided to EFSA
1) Letter from the European Commission to EFSA received on 23 August 2018 concerning a
request for the continued marketing of genetically modiﬁed maize MIR604 in accordance
with articles 11 and 23 of Regulation (EC) No 1829/2003 by Syngenta Crop Protection NV/SA
(EFSA-GMO-RX-013).
2) Application EFSA-GMO-RX-013 validated by EFSA, 5 November 2018.
3) Request for supplementary information to the applicant, 28 November 2018.
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4) Request for supplementary information to the applicant, 21 December 2018.
5) Receipt of supplementary information from the applicant, 22 February 2019.
6) Request for supplementary information to the applicant, 10 April 2019.
7) Receipt of supplementary information from the applicant, 2 May 2019.
8) Receipt of supplementary information from the applicant, 15 May 2019.
9) Receipt of spontaneous information from the applicant, 5 September 2019.
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Appendix A – List of relevant publications identiﬁed by the applicant
through the systematic literature search (January 2007 – March 2019)
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Chen E and Defontes C, 2014. Transgenic plants expressing modiﬁed CRY3A. Ofﬁcial Gazette of the United
States Patent & Trademark Ofﬁce Patents (Jun 24).
Chen E and Defontes C. 2012. Modiﬁed Cry3A toxins and nucleic acid sequences coding therefor. Ofﬁcial Gazette
of the United States Patent & Trademark Ofﬁce Patents (Aug 21).
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Chen E and Stacy C, 2012. Modiﬁed Cry3A toxins and nucleic acid sequences coding therefor. Ofﬁcial Gazette of
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Tyshko NV, Britsina MV, Gmoshinsky IV, Zhanataev NS, Zorin SN, Mazo VK, Ozeretskovskaia MN, Semenov BF,
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Appendix B – List of additional studies performed by or on behalf of the
applicant over the course of the authorisation period and not previously
submitted to the EU with regard to the evaluation of the safety of the food
and feed for humans, animal or the environment from maize MIR604
Study identiﬁcation Title
SSB-219-10 Quantiﬁcation of mCry3A and MIR604 PMI in event MIR604 maize
tissues grown in Romania in 2008
SSB-005-10 Quantiﬁcation of mCry3A and MIR604 PMI in event MIR604 maize
tissues grown in Spain in 2008
SSB-112-10 (Vols 1 and 2) Compositional analysis of forage and grain from an MIR604 hybrid
maize grown during 2008 in Europe
EPD-100-10-A1 Agronomic assessment of event MIR604 maize under European
growing conditions in 2008
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